Contineum Therapeutics closed at $9.62 on Nov 4, down 0.72%, 45.2% below its 52-week closing high. Volume of 549.2K shares was 0.41× its 20-day average (below normal).
Split-adjusted performance: -24.0% over one month, -35.6% over six months, -9.7% over one year.
Short interest was 3.7M shares at the Oct 15 settlement, up 19.2% from the prior report (13.1% of float, 2.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CTNMContineum Therapeutics | $9.62 | −0.72% | −35.6% | — | — | — | $361.9M | |
| MPLTMapLight Therapeutics | $6.67 | −2.13% | −77.0% | — | — | — | $370.4M | Compare |
| IRDOpus Genetics | $4.23 | +7.63% | −19.6% | −73.8% | −1072.6% | — | $351.9M | Compare |
| GALTGalectin Therapeutics | $3.48 | +3.88% | +54.7% | — | — | — | $351.0M | Compare |
| AVIRAtea Pharmaceuticals | $4.37 | +4.80% | −22.7% | — | — | — | $350.5M | Compare |
| BLSMBlossomHill Therapeutics | $11.91 | −4.03% | — | — | — | — | $378.6M | Compare |
| LYELLyell Immunopharma | $15.59 | +44.75% | −25.2% | −50.0% | −1118875.0% | — | $382.0M | Compare |
| AVTXAvalo Therapeutics | $7.13 | −1.66% | −67.3% | — | — | — | $382.4M | Compare |
| RZLTRezolute, Inc. Common Stock (NV) | $4.08 | +1.75% | +29.9% | — | — | — | $394.6M | Compare |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
